Skip to main content

Table 4 Multivariate analysis of the factors associated with dispensation of celecoxib and rofecoxib versus traditional nonselective NSAIDs

From: Prescription channeling of COX-2 inhibitors and traditional nonselective nonsteroidal anti-inflammatory drugs: a population-based case–control study

  Celecoxib Rofecoxib
Age group   
   75+ 5.34 (4.96–5.75) 3.06 (2.83–3.30)
   55 to ≤74 3.65 (3.45–3.87) 2.62 (2.46–2.78)
   18–54 Reference Reference
Female sex 1.55 (1.47–1.62) 1.45 (1.38–1.52)
Income level (lower) 0.95 (0.88–1.02) 0.83 (0.77–0.89)
Prior diagnosis of gastropathy 1.21 (1.07–1.37) 1.11 (0.97–1.27)
Prior gastrointestinal procedures 1.21 (1.02–1.42) 0.97 (0.81–1.16)
Prior dispensation of gastroprotective agents 1.59 (1.48–1.71) 1.51 (1.41–1.63)
Prior referral to gastroenterologist 1.27 (1.11–1.45) 1.19 (1.03–1.37)
Prior history of NSAID use:   
   Recent, first time 2.25 (1.99–2.54) 2.02 (1.79–2.29)
   Recent, chronic 1.68 (1.52–1.85) 0.75 (0.68–0.84)
   >1 to 3 months 1.36 (1.26–1.45) 0.48 (0.44–0.52)
   >3 to 12 months 0.85 (0.80–0.91) 0.81 (0.76–0.87)
   No use in past year Reference Reference
Corticosteroids 1.11 (1.02–1.20) 1.20 (1.11–1.31)
Anticoagulants 1.61 (1.34–1.94) 1.48 (1.23–1.78)
Antidepressants 1.38 (1.28–1.48) 1.37 (1.27–1.48)
Benzodiazepines 1.18 (1.12–1.25) 1.15 (1.09–1.22)
Acetaminophen 1.39 (1.31–1.48) 1.37 (1.28–1.45)
Low-dose ASA 0.67 (0.62–0.71) 0.58 (0.54–0.62)
Chronic Disease Score   
   10+ 1.26 (1.11–1.43) 1.20 (1.06–1.37)
   5–9 1.28 (1.19–1.38) 1.23 (1.14–1.33)
   1–4 1.25 (1.17–1.33) 1.26 (1.18–1.34)
   0 Reference Reference
Physician specialty 0.96 (0.90–1.03) 0.83 (0.77–0.89)
Dosage   
   High dose 3.36 (3.15–3.58) 0.76 (0.70–0.82)
   Low dose 0.09 (0.09–0.10) 0.73 (0.69–0.78)
   Standard dose Reference Reference
Time period   
   January–June 1.25 (1.16–1.34) 0.24 (0.22–0.26)
   July–September 1.09 (1.00–1.19) 0.93 (0.87–1.01)
   October–December Reference Reference
  1. ASA, acetylsalicylic acid; NSAID, nonsteroidal anti-inflammatory drug.